Bibliography
- Lazarou J , PomeranzB, CoreyP: Incidence of adverse drug reactions in hospitalized patients.JAMA279, 1200–1205 (1998).
- Lewis DFV : 57 Varieties: The human cytochromes P450.Pharmacogenomics5, 305–318 (2004).
- Piper MA : Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. BlueCross BlueShield Association.Technology Evaluation Center Volume 10(9) (2004).
- Meyer UA , ZangerUM: Molecular mechanisms of genetic polymorphisms of drug metabolism.Annu. Rev. Pharmacol. Toxicol.37, 269–296 (1997).
- Kirchheiner J , Tsaburidu,M Jabrane W et al.: The 2C9 polymorphism: from enzyme to clinical dose recommendations. Personalized Med.1, 63–84 (2004).
- Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and the antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry9, 442–473 (2004).
- Ruano G , ThompsonPD, WindemuthA et al.: Physiogenomic analysis links serum creatinine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics6(8), 865–872 (2005).
- Gordon J , MeranteF, WeissS et al.: Pharmacogenetic P450 screening using the Tag-It™ universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling The Practice of Personalized Medicine. Valdes R, Linder M, Wong S (Eds). AACC Press, Washington, DC, USA (In press) (2006).
- Wilke R , MooreJ, BurmesterJ et al.: Relative impact of CYP3A4 genotype and concomitant medication on the severity of artorvastatin-induced muscle damage. Pharmacogenet. Genomics15, 415–421 (2005).
- Droll K , Bruce-MensahK, OttonSV et al.: Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics8, 325–333 (1998).
- McLellan R , OscarsonM, SeidegardJ et al.: Frequent occurrences of CYP2D6 gene duplications in Saudi Arabians. Pharmacogenetics7, 187–191 (1988).
- Xie HG , PrasadHC, KimRB, SteinCM: CYP2C9 allelic variants: ethnic distribution and functional significance.Adv. Drug Deliv. Rev.54, 1257–1270 (2002).
- Wilkerson GR : Drug metabolism and variability among patients in drug response.N. Engl. J. Med.352, 2211–2224 (2005).
- Andersson T , FlockhartDA, GoldsteinDB et al.: Drug metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther.78, 559–581 (2005).
- deLeon J , ArmstrongSC, CozzaK: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and 2C19. Psychosomatics47, 1–12 (2006).
- Mrazek DA : Clinical implementation of psychiatric pharmacogenomic testing.Personalized Med.2, 93–95 (2005).
- Higashi MK , VeenstraDL, KondoL et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA287, 1690–1698 (2002).
- Linder MW , LooneyS, AdamsJE et al.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.J. Thrombosis Thrombolysis14(3), 227–232 (2002).
- Womack C : As part of retrofitting, FDA panel votes to relabel warfarin for PGx; Is Dx far behind?Pharmacogenomics Reporter, December 1 (2005).
- Ruano G : Quo vadis personalized medicine?Personalized Med.1, 1–7 (2004).
Websites
- Human Cytochrome P450 (CYP) Allele Nomenclature Committee. www.imm.ki.se/CYPalleles/
- US FDA’s Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science. Update on previous Clinical Pharmacology Subcommittee meeting recommendations; www.fda.gov/OHRMS/DOCKETS/AC/05/slides/2005–4194S1_Slide-Index.htm